1.14
+0.24(+26.67%)
Currency In USD
| Previous Close | 0.9 |
| Open | 1.4 |
| Day High | 1.48 |
| Day Low | 1.12 |
| 52-Week High | 4.19 |
| 52-Week Low | 0.81 |
| Volume | 159.79M |
| Average Volume | 375,732 |
| Market Cap | 12.27M |
| PE | -0.53 |
| EPS | -2.15 |
| Moving Average 50 Days | 1.1 |
| Moving Average 200 Days | 1.86 |
| Change | 0.24 |
If you invested $1000 in Phio Pharmaceuticals Corp. (PHIO) 10 years ago, it would be worth $0.01 as of February 10, 2026 at a share price of $1.14. Whereas If you bought $1000 worth of Phio Pharmaceuticals Corp. (PHIO) shares 5 years ago, it would be worth $3.17 as of February 10, 2026 at a share price of $1.14.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Phio Announces Safety Monitoring Committee's (SMC) Positive Wrap-up on Lead Clinical Candidate PH-762 in Skin Cancer Trial
Newsfile
10 hours ago
Maximum Dose Concentration in Final Cohort Yields 85% Pathological Response (6 of 7 Patients); Complete Response (100% Tumor Clearance) in 4 of 6 RespondersNo Serious Adverse Events or Dose-Limiting Toxicities Identified Across All 5 Dose Escalation
Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference
Newsfile
Jan 26, 2026 1:15 PM GMT
Phio's Presentation to take place on Wednesday January 28, 2026 at 9 AM ETKing of Prussia, Pennsylvania--(Newsfile Corp. - January 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing th
Phio Pharmaceuticals Announces Key Tumor Response Data from all Cohorts in Intratumoral PH-762 Dose Escalation Cutaneous Carcinoma Trial
Newsfile
Jan 20, 2026 2:30 PM GMT
Pathology data indicate 70% overall response rate for squamous cell carcinomas: 100% clearance in 10 out of 14 responders Favorable safety and tolerability at all dose escalations King of Prussia, Pennsylvania--(Newsfile Corp. - January 20, 2026) - P